HK Stock Market Move | ALPHAMAB-B(09966) surged over 24% with the completion of the first patient dosing in the JSKN003 clinical trial for stage III HER2-positive breast cancer.

ALPHAMAB-B (09966) rose more than 24% in the afternoon, as of the time of writing, it increased by 24.75% to 6.2 Hong Kong dollars with a trading volume of 160 million Hong Kong dollars. In terms of news, Kangning Jerui Biopharmaceutical and CSPC PHARMA jointly announced that the Phase III clinical trial (Study Number: JSKN003-301) comparing HER2 bispecific antibody-drug conjugate (ADC) JSKN003 with trastuzumab emtansine (T-DM1) in the treatment of HER2-positive advanced breast cancer has dosed its first patient. The company stated that the Phase III clinical trials for JSKN003 in the treatment of HER2 low-expressing breast cancer (JSKN003-302) and platinum-resistant ovarian cancer (JSKN003-306) are also progressing smoothly. Soochow previously mentioned that JSKN003 is the company's first ADC product in its transformation, targeting DS-8201. It is worth noting that Hang Seng Index Company recently announced the results of its regular quarterly index adjustments. The adjustments will take effect from March 10th. Among them, Kangning Jerui Pharmaceuticals has been removed from the Hang Seng Composite Index.